OP0033 FIBROBLAST GENE, FKBP7 INDUCED BY Ca2+ DEPENDENT ER STRESS ASSOCIATED WITH CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE; MULTI-CENTRE GWAS AND FUNCTIONAL STUDIES
Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Obje...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 83; no. Suppl 1; pp. 28 - 29 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
BMJ Publishing Group Ltd and European League Against Rheumatism
01.06.2024
Elsevier B.V Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0003-4967 1468-2060 |
DOI | 10.1136/annrheumdis-2024-eular.2788 |
Cover
Abstract | Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/groupAcknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared. |
---|---|
AbstractList | Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/groupAcknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared. Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity. To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies. The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin. Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity. We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets. [1] Zhang et al, 2019, Nat Imm. [2] Lewis et al, 2019, Cell Rep. [3] Thalayasingam et al, 2018, A&R. [4] Warner et al, 2013, Sci. Signal. [5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet. We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer. Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared. [Display omitted] [Display omitted] Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).[Figure omitted. See PDF]Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/group[Figure omitted. See PDF]Acknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared. |
Author | Martin, P. Porter, D. Taylor, J. Barton, A. Ospelt, C. Huizinga, T. Klareskog, L. Cope, A. Pitzalis, C. Pratt, A. Nagafuchi, Y. Goodyear, C. S. González-Álvaro, I. Hu, X. Morton, F. Van den Akker, E. B. Jelinsky, S. Eyre, S. Emery, P. Toes, R. E. M. Micheroli, R. Westerlind, H. Naamane, N. Reynard, L. Van der Helm – van Mil, A. H. M. Jurado-Zapata, S. Morgan, A. Rodriguez Rodriguez, L. Winkler, A. Lendrem, D. Böhringer, S. Cameron, A. Mc Innes, I. B. Orozco, G. Thomas, R. Paterson, C. Gaddi, V. P. Studenic, P. Lewis, M. Plant, D. Isaacs, J. Abasolo, L. Knevel, R. Blüml, S. Askling, J. Padyukov, L. Johannesson, M. Sieghart, D. Verstappen, S. Maurits, M. P. Vaskimo, L. De, S. |
Author_xml | – sequence: 1 givenname: M. P. surname: Maurits fullname: Maurits, M. P. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 2 givenname: A. surname: Cameron fullname: Cameron, A. organization: University of Queensland, Brisbane, Australia – sequence: 3 givenname: S. surname: Jelinsky fullname: Jelinsky, S. organization: Pfizer, New York City, United States of America – sequence: 4 givenname: S. surname: Blüml fullname: Blüml, S. organization: Medical University of Vienna, Vienna, Austria – sequence: 5 givenname: L. surname: Abasolo fullname: Abasolo, L. organization: Hospital Clínico San Carlos, Madrid, Spain – sequence: 6 givenname: J. surname: Askling fullname: Askling, J. organization: Karolinska Institutet, Stockholm, Sweden – sequence: 7 givenname: A. surname: Barton fullname: Barton, A. organization: University of Manchester, Manchester, United Kingdom – sequence: 8 givenname: S. surname: Böhringer fullname: Böhringer, S. organization: Leiden University Medical Center, Medical Statistics, Leiden, Netherlands – sequence: 9 givenname: A. surname: Cope fullname: Cope, A. organization: King’s College London, London, United Kingdom – sequence: 10 givenname: S. surname: De fullname: De, S. organization: Pfizer, New York City, United States of America – sequence: 11 givenname: P. surname: Emery fullname: Emery, P. organization: University of Leeds, Leeds, United Kingdom – sequence: 12 givenname: S. surname: Eyre fullname: Eyre, S. organization: University of Manchester, Manchester, United Kingdom – sequence: 13 givenname: V. P. surname: Gaddi fullname: Gaddi, V. P. organization: University of Manchester, Manchester, United Kingdom – sequence: 14 givenname: I. surname: González-Álvaro fullname: González-Álvaro, I. organization: Hospital Universitario de La Princesa, Madrid, Spain – sequence: 15 givenname: C. S. surname: Goodyear fullname: Goodyear, C. S. organization: University of Glasgow, Glasgow, United Kingdom – sequence: 16 givenname: X. surname: Hu fullname: Hu, X. organization: Pfizer, New York City, United States of America – sequence: 17 givenname: T. surname: Huizinga fullname: Huizinga, T. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 18 givenname: M. surname: Johannesson fullname: Johannesson, M. organization: Karolinska Institutet, Stockholm, Sweden – sequence: 19 givenname: S. surname: Jurado-Zapata fullname: Jurado-Zapata, S. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 20 givenname: L. surname: Klareskog fullname: Klareskog, L. organization: Karolinska Institutet, Stockholm, Sweden – sequence: 21 givenname: D. surname: Lendrem fullname: Lendrem, D. organization: Newcastle University, Newcastle, United Kingdom – sequence: 22 givenname: P. surname: Martin fullname: Martin, P. organization: University of Manchester, Manchester, United Kingdom – sequence: 23 givenname: I. B. surname: Mc Innes fullname: Mc Innes, I. B. organization: University of Glasgow, Glasgow, United Kingdom – sequence: 24 givenname: R. surname: Micheroli fullname: Micheroli, R. organization: University Hospital Zurich, Zurich, Switzerland – sequence: 25 givenname: A. surname: Morgan fullname: Morgan, A. organization: University of Leeds, Leeds, United Kingdom – sequence: 26 givenname: F. surname: Morton fullname: Morton, F. organization: University of Glasgow, Glasgow, United Kingdom – sequence: 27 givenname: N. surname: Naamane fullname: Naamane, N. organization: Newcastle University, Newcastle, United Kingdom – sequence: 28 givenname: Y. surname: Nagafuchi fullname: Nagafuchi, Y. organization: University of Tokyo, Tokyo, Japan – sequence: 29 givenname: G. surname: Orozco fullname: Orozco, G. organization: University of Manchester, Manchester, United Kingdom – sequence: 30 givenname: L. surname: Padyukov fullname: Padyukov, L. organization: Karolinska Institutet, Stockholm, Sweden – sequence: 31 givenname: C. surname: Paterson fullname: Paterson, C. organization: University of Glasgow, Glasgow, United Kingdom – sequence: 32 givenname: C. surname: Pitzalis fullname: Pitzalis, C. organization: Queen Mary University of London, London, United Kingdom – sequence: 33 givenname: D. surname: Plant fullname: Plant, D. organization: University of Manchester, Manchester, United Kingdom – sequence: 34 givenname: D. surname: Porter fullname: Porter, D. organization: University of Glasgow, Glasgow, United Kingdom – sequence: 35 givenname: L. surname: Reynard fullname: Reynard, L. organization: Newcastle University, Newcastle, United Kingdom – sequence: 36 givenname: L. surname: Rodriguez Rodriguez fullname: Rodriguez Rodriguez, L. organization: Hospital Clínico San Carlos, Madrid, Spain – sequence: 37 givenname: D. surname: Sieghart fullname: Sieghart, D. organization: Medical University of Vienna, Vienna, Austria – sequence: 38 givenname: P. surname: Studenic fullname: Studenic, P. organization: Medical University of Vienna, Vienna, Austria – sequence: 39 givenname: J. surname: Taylor fullname: Taylor, J. organization: University of Leeds, Leeds, United Kingdom – sequence: 40 givenname: R. E. M. surname: Toes fullname: Toes, R. E. M. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 41 givenname: E. B. surname: Van den Akker fullname: Van den Akker, E. B. organization: Leiden University Medical Center, Biomedical Data Sciences, Leiden, Netherlands – sequence: 42 givenname: A. H. M. surname: Van der Helm – van Mil fullname: Van der Helm – van Mil, A. H. M. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 43 givenname: L. surname: Vaskimo fullname: Vaskimo, L. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands – sequence: 44 givenname: S. surname: Verstappen fullname: Verstappen, S. organization: University of Manchester, Manchester, United Kingdom – sequence: 45 givenname: H. surname: Westerlind fullname: Westerlind, H. organization: Karolinska Institutet, Stockholm, Sweden – sequence: 46 givenname: J. surname: Isaacs fullname: Isaacs, J. organization: Newcastle University, Newcastle, United Kingdom – sequence: 47 givenname: M. surname: Lewis fullname: Lewis, M. organization: Queen Mary University of London, London, United Kingdom – sequence: 48 givenname: A. surname: Pratt fullname: Pratt, A. organization: Newcastle University, Newcastle, United Kingdom – sequence: 49 givenname: C. surname: Ospelt fullname: Ospelt, C. organization: University Hospital Zurich, Zurich, Switzerland – sequence: 50 givenname: A. surname: Winkler fullname: Winkler, A. organization: Pfizer, New York City, United States of America – sequence: 51 givenname: R. surname: Thomas fullname: Thomas, R. organization: University of Queensland, Brisbane, Australia – sequence: 52 givenname: R. surname: Knevel fullname: Knevel, R. organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands |
BookMark | eNqNkU9u1DAYxS1UJKaFO1jqElLsOJM46iqTeCYWmWQUO6pYWfnjERl1kuJ0kNh1wyG4C6fpSfAQJFh2Zdl-7_c--12Ci2EcNADXGN1gTPyP9TCYL_p07PrJcZHrOfp0X5sbN6D0FVhgz6f22EcXYIEQIo4X-sEbcDlNB7tFFNMF-FXs7A15fvqx5quyWGWRkHDDcvYBrj-tdgHkeVLFLIGrzzCu3fcwYTuWJyyXkJVQyJIJASMhiphH0sruuExhnPGcx1EGi0rGxZZZCCxTVm0jWfAERqVMSy65NeYJjMsizZ-ffgqYcMEiwW7htsokd2IbUjK4uYtm4brKY8mL3HKFrBLOxFvwel_fT_rd3_UKVGsm49TJis0532lwiJBDPIpqhAIPk7Z19w1CbUu6cB94etk0lHQoXDaUBnW7DGvq1y6mQRciHCwb34oxuQLXM_fBjF9PenpUh_FkBhupCEYotP9NkFXdzqrWjNNk9F49mP5Ym-8KI3WuS_1XlzrXpf7Upc51WTeb3do-5FuvjZraXg-t7nqj20fVjf0LOcHMaY6Hf2O-xPkbVPeuXQ |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. – notice: 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
DBID | AAYXX CITATION K9. |
DOI | 10.1136/annrheumdis-2024-eular.2788 |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 29 |
ExternalDocumentID | 10_1136_annrheumdis_2024_eular_2788 S0003496724150285 annrheumdis |
GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 0R~ AAFWJ AALRI PHGZM PJZUB PPXIY PQGLB AAYXX CITATION K9. |
ID | FETCH-LOGICAL-b1900-3480a007413cc2fb00cc3d9f74e5bb83d095b887ac59a86a2187d90175b6b0013 |
ISSN | 0003-4967 |
IngestDate | Fri Jul 25 10:58:53 EDT 2025 Thu Jul 31 00:38:46 EDT 2025 Sat Aug 23 17:13:03 EDT 2025 Thu Apr 24 22:50:08 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Keywords | Fibroblasts Genetics Remission |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b1900-3480a007413cc2fb00cc3d9f74e5bb83d095b887ac59a86a2187d90175b6b0013 |
Notes | EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
PQID | 3100927830 |
PQPubID | 2041045 |
PageCount | 2 |
ParticipantIDs | proquest_journals_3100927830 crossref_primary_10_1136_annrheumdis_2024_eular_2788 elsevier_sciencedirect_doi_10_1136_annrheumdis_2024_eular_2788 bmj_journals_10_1136_annrheumdis_2024_eular_2788 |
PublicationCentury | 2000 |
PublicationDate | 2024-June June 2024 2024-06-00 20240601 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-June |
PublicationDecade | 2020 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington |
PublicationTitle | Annals of the rheumatic diseases |
PublicationTitleAbbrev | Ann Rheum Dis |
PublicationYear | 2024 |
Publisher | BMJ Publishing Group Ltd and European League Against Rheumatism Elsevier B.V Elsevier Limited |
Publisher_xml | – name: BMJ Publishing Group Ltd and European League Against Rheumatism – name: Elsevier B.V – name: Elsevier Limited |
SSID | ssj0000818 |
Score | 2.4508007 |
Snippet | Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms.... Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid... |
SourceID | proquest crossref elsevier bmj |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 28 |
SubjectTerms | Actin Autoimmune diseases Biomedical research Biopsy Blood levels Calcium (reticular) CD4 antigen Conflicts of interest Consortia Crohn's disease Endoplasmic reticulum Fibroblasts Gene expression Genes Genetics Haplotypes Immunological diseases Inflammatory bowel diseases Lymphocytes B Lymphocytes T Medical research Medical treatment Monocytes NOD2 protein Osteoarthritis Patients Protein folding Remission Remission (Medicine) Rheumatoid arthritis Scientific Abstracts Tacrolimus Tacrolimus-binding protein |
Title | OP0033 FIBROBLAST GENE, FKBP7 INDUCED BY Ca2+ DEPENDENT ER STRESS ASSOCIATED WITH CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE; MULTI-CENTRE GWAS AND FUNCTIONAL STUDIES |
URI | https://ard.bmj.com/content/83/Suppl_1/28.full https://dx.doi.org/10.1136/annrheumdis-2024-eular.2788 https://www.proquest.com/docview/3100927830 |
Volume | 83 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVPQU databaseName: AUTh Library subscriptions: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1468-2060 dateEnd: 20241231 omitProxy: true ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: BENPR dateStart: 19390101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: true ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: 7X7 dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FVqq4IJ6ipVQrAafFwbEdP4SE5FewS-JEfoj0ZNmOLYTagEpy4cTf4K_wc7jzH5hdrx9qAYVerGiVHe9mvux8szs7g9DzKi-VKqsKIS8kTVDAQgqAG3Bcs6rMxEopxIJF-Qaqlyiny_FyMPjVi1rabvJh8fWP90puolVoA73SW7L_odlWKDTAZ9AvPEHD8NxJx_MFLZJGJr4Vzq2pGcWERqIxPvrOWmjED5zEdh1inRE7k15IFnHchRs4bhATusEU05-_zuzom7CEgTsfe8Se-gHLkjBPYns-o0XpSei5ycyM575DgAF7oR_7EctMZYdzL2giJoyIOH7kmpFLKwPMkmnsCza8LHTJ2_dm3WGSBDZPwNtno9fyObPQxw_ltk4py8-RWgdgRrMhbeqd8uFi2DtJKS95ley28ZReued7xFHbap3TGAHLvjjvtfPtD0npwrTaJV0WFKOu6dEs6brcX5P1nnWvt1eu2w2ZJ0xmE4M5CexdJQ0FHkqarnfmsgkRuGJF29hG5lXJ7KZ3IyylwlImLKXCbqF9SVNVWnBDW2odcdBHelPgkc7oAD3jY3v1j5EBKcovPv6NVl0hGIw1xXfRHe7uYLPG7j00KNf30cGMB3Q8QD9qCOMOwphC-CVmAMYcwNg6wwBgglv4YjfENXxxB19M4Ysb-GIOXxCCO_jiFr4Y0IgZfH9--x5hDtzXuA9bTGHLvtjBFnPYPkTJxI1tT-DlRIQcWC-wDUUXM0ah5aKQKrA3RSGvjEpTynGe6_IKvI0cbG5WjI1MVzMgv9oK6LI2zlXqW8iP0N7607p8jPCozEVdKYyRoQMjLrQsA09ehC6yoebVaHSIRNBJypeKL-kOmDhESqPA9HOdaGa3bm8aZaecM9dcOAVo7ybguIFIN1566mfQGjzi0c2G9QTd7v6sx2hvc7ktnwJ73-QnDPMnaN9yg0X4GyzD1pA |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP0033+FIBROBLAST+GENE%2C+FKBP7+INDUCED+BY+Ca2%2B+DEPENDENT+ER+STRESS+ASSOCIATED+WITH+CLINICAL+OUTCOME+IN+RHEUMATOID+ARTHRITIS+AND+CROHN%E2%80%99S+DISEASE%3B+MULTI-CENTRE+GWAS+AND+FUNCTIONAL+STUDIES&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Maurits%2C+M.P.&rft.au=Cameron%2C+A.&rft.au=Jelinsky%2C+S.&rft.au=Bl%C3%BCml%2C+S.&rft.date=2024-06-01&rft.issn=0003-4967&rft.volume=83&rft.spage=28&rft.epage=29&rft_id=info:doi/10.1136%2Fannrheumdis-2024-eular.2788&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_annrheumdis_2024_eular_2788 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |